|Bid||479.10 x 800|
|Ask||484.29 x 1200|
|Day's range||476.72 - 486.90|
|52-week range||343.19 - 532.57|
|Beta (5Y monthly)||0.77|
|PE ratio (TTM)||24.33|
|Earnings date||20 Jul 2021 - 26 Jul 2021|
|Forward dividend & yield||1.04 (0.22%)|
|Ex-dividend date||15 Mar 2021|
|1y target est||550.29|
Thermo Fisher's (TMO) enhanced Quick to Clinic solution provides balance of speed and quality to accelerate and advance DNA to Investigational New Drug in as less as 13 months.
In academic and government end markets, Thermo Fisher (TMO) grows on robust customer activity globally.
Watch out for names like Onto Innovation (ONTO), DuPont de Nemours (DD), Thermo Fisher Scientific (TMO) and International Business Machines (IBM) as the nanotechnology market continues to grow.